Oxurion Receives Transparency Notifications Based on New Denominator
Leuven, BELGIUM, Boston, MA, US –November 17, 2022 –8 AM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group Ltd., the updated denominator for transparency notifications was 109,075,765 shares as of November 11, 2022: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Oxurion NV)
Oxurion received transparency notification from Negma Group indicating that as of November 16, it holds 0 common shares. Oxurion also received transparency notification from Fidelity Management & Research Company LLC that their 3,128,819 common shares have crossed below the lowest threshold (3%) by virtue of a downward passive crossing.
In addition, by virtue of a downward passive crossing, the following thresholds have been crossed:
- Novartis Pharma AG’s 2,177,226 shares have crossed below the lowest threshold (3%)
- Philippe Vlerick/Balderma SA’s 3,580,787 shares have crossed below the lowest threshold (3%)
- Thomas M. Clay’s 4,542,110 shares have crossed below the 5% threshold
Content of the latest Negma Group Ltd. Notification
Reason of the notification
Acquisition or disposal of voting securities or voting rights
Notifications by
A person that notifies alone
Threshold that is crossed
Downward crossing of the lowest threshold
Denominator
109,075,765
Chain of controlled undertakings through which the holding is effectively held
Not applicable
Notified details
See Annex 1 for this and prior transparency notification of November
Content of the Fidelity Management & Research Company LLC Notification
Reason of the notification
Passive crossing of a threshold
Downward crossing of the lowest threshold
Notifications by
A parent undertaking or a controlling person
Threshold that is crossed
3%
Denominator
109,075,765
Notified details
See Annex 2
Chain of controlled undertakings through which the holding is effectively held
Fidelity Management & Research Company LLC is controlled by FMR LLC.
FMR LLC is not a controlled entity
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com | US Conway Communications Beth Kurth bkurth@conwaycommsir.com ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com |
ANNEX 1
Negma notification of November 16, 2022
A)Votingrights | Previousnotification | Afterthetransaction | |||||
#ofvotingrights | #ofvotingrights | %ofvotingrights | |||||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |||
Elaf Gassam | 0 | 0 | - | ||||
Negma Group Investment Ltd. | 0 | 0 | - | ||||
Negma Group Ltd. | 16,250,000 | 0 | - | ||||
Subtotal | 16,250,000 | 0 | + |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
B)Equivalentfinancialinstruments | Afterthetransaction | ||||||
Holdersofequivalentfinancialinstruments | Typeoffinancialinstrument | Expirationdate | Exerciseperiodordate | #ofvotingrightsthat may beacquired if theinstrumentisexercised | %ofvotingrights | Settlement | |
+ | |||||||
TOTAL | 0 | 0.00% |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.Thetotalswillbeupdatedonceyouhaveclickedon<CALCULATE>
TOTAL(A& B) | #ofvotingrights | %ofvotingrights | |
CALCULATE | 0 | 0.00% |
Negma notification of November 8, 2022
A)Votingrights | Previousnotification | Afterthetransaction | |||||
#ofvotingrights | #ofvotingrights | %ofvotingrights | |||||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |||
02/11/2022: Negma Group Ltd. Threshold: + 15 % | 0 | 15,000,000 | 16.16% | - | |||
03/11/2022: Negma Group Ltd. Threshold: - 10 % | 8,828,255 | - | |||||
04/11/2022: Negma Group Ltd | 8,750,000 | - | |||||
7/11/2022: Negma Group Ltd. Threshold: - 3 % (see section 13) | 0 | - | |||||
Subtotal | 15,000,000 | 16.16% | + | ||||
TOTAL | 15,000,000 | 0 | 16.16% | 0.00% |
B)Equivalentfinancialinstruments | Afterthetransaction | ||||||
Holdersofequivalentfinancialinstruments | Typeoffinancialinstrument | Expirationdate | Exerciseperiodordate | #ofvotingrightsthat may beacquired if theinstrumentisexercised | %ofvotingrights | Settlement | |
+ | |||||||
TOTAL | 0 | 0.00% |
TOTAL(A& B) | #ofvotingrights | %ofvotingrights | |
CALCULATE | 15,000,000 | 16.16% |
ANNEX 2
B)Equivalentfinancialinstruments | Afterthetransaction | ||||||
Holdersofequivalentfinancialinstruments | Typeoffinancialinstrument | Expirationdate | Exerciseperiodordate | #ofvotingrightsthat may beacquired if theinstrumentisexercised | %ofvotingrights | Settlement | |
Fidelity Management & Research Company LLC | Stock Loan | 90,401 | 0.08% | physical | + | ||
TOTAL | 90,401 | 0.08% |
TOTAL(A&B) | #ofvotingrights | %ofvotingrights | |
CALCULATE | 3,128,819 | 2.87% |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release
First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by
SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release
SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti
Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior
Nokia Corporation: Repurchase of own shares on 07.05.20247.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 07 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 07.05.2024 Espoo, Finland – On 07 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL376,2023.48CEUX--BATE--AQEU--TQEX--Total376,2023.48 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra